دورية أكاديمية
Recent advances in c-Met-based dual inhibitors in the treatment of cancers.
| العنوان: | Recent advances in c-Met-based dual inhibitors in the treatment of cancers. |
|---|---|
| المؤلفون: | Jin F; College of Pharmacy of Liaoning University, Shenyang, Liaoning, 110036, PR China., Lin Y; College of Pharmacy of Liaoning University, Shenyang, Liaoning, 110036, PR China., Yuan W; College of Pharmacy of Liaoning University, Shenyang, Liaoning, 110036, PR China., Wu S; College of Pharmacy of Liaoning University, Shenyang, Liaoning, 110036, PR China., Yang M; College of Pharmacy of Liaoning University, Shenyang, Liaoning, 110036, PR China., Ding S; College of Pharmacy of Liaoning University, Shenyang, Liaoning, 110036, PR China; API Engineering Technology Research Center of Liaoning Province, Shenyang, Liaoning, 110036, PR China; Small Molecular Targeted Drug R&D Engineering Research Center of Liaoning Province, Shenyang, Liaoning, 110036, PR China., Liu J; College of Pharmacy of Liaoning University, Shenyang, Liaoning, 110036, PR China; API Engineering Technology Research Center of Liaoning Province, Shenyang, Liaoning, 110036, PR China; Small Molecular Targeted Drug R&D Engineering Research Center of Liaoning Province, Shenyang, Liaoning, 110036, PR China. Electronic address: liuju1216@126.com., Chen Y; College of Pharmacy of Liaoning University, Shenyang, Liaoning, 110036, PR China; API Engineering Technology Research Center of Liaoning Province, Shenyang, Liaoning, 110036, PR China; Small Molecular Targeted Drug R&D Engineering Research Center of Liaoning Province, Shenyang, Liaoning, 110036, PR China. Electronic address: sy-chenye@163.com. |
| المصدر: | European journal of medicinal chemistry [Eur J Med Chem] 2024 Jun 05; Vol. 272, pp. 116477. Date of Electronic Publication: 2024 May 08. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Editions Scientifiques Elsevier Country of Publication: France NLM ID: 0420510 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1768-3254 (Electronic) Linking ISSN: 02235234 NLM ISO Abbreviation: Eur J Med Chem Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Paris : Editions Scientifiques Elsevier Original Publication: Paris, S.E.C.T. [etc.] |
| مواضيع طبية MeSH: | Proto-Oncogene Proteins c-met*/antagonists & inhibitors , Proto-Oncogene Proteins c-met*/metabolism , Neoplasms*/drug therapy , Neoplasms*/pathology , Protein Kinase Inhibitors*/pharmacology , Protein Kinase Inhibitors*/chemistry , Protein Kinase Inhibitors*/chemical synthesis , Antineoplastic Agents*/pharmacology , Antineoplastic Agents*/chemistry , Antineoplastic Agents*/therapeutic use , Proto-Oncogene Mas*, Humans ; Structure-Activity Relationship ; Molecular Structure ; Cell Proliferation/drug effects ; Animals |
| مستخلص: | The cellular-mesenchymal epithelial transition factor (c-Met) is a receptor tyrosine kinase (RTK) located on the 7q31 locus encoding the Met proto-oncogene and plays a critical role in regulating cell proliferation, metastasis, differentiation, and apoptosis through various signaling pathways. However, its aberrant activation and overexpression have been implicated in many human cancers. Therefore, c-Met is a promising target for cancer treatment. However, the anticancer effect of selective single-targeted drugs is limited due to the complexity of the signaling system and the involvement of different proteins and enzymes. After inhibiting one pathway, signal molecules can be transmitted through other pathways, resulting in poor efficacy of single-targeted drug therapy. Dual inhibitors that simultaneously block c-Met and another factor can significantly improve efficacy and overcome some of the shortcomings of single-target inhibitors, including drug resistance. In this review, We introduced c-Met kinase and the synergism between c-Met and other anti-tumor targets, then dual-target inhibitors based on c-Met for the treatment of cancers were summarized and their design concepts and structure-activity relationships (SARs) were discussed elaborately, providing a valuable insight for the further development of novel c-Met-based dual inhibitors. Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (Copyright © 2024 Elsevier Masson SAS. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Anticancer; Dual target inhibitors; SARs; c-Met |
| المشرفين على المادة: | EC 2.7.10.1 (Proto-Oncogene Proteins c-met) 0 (Protein Kinase Inhibitors) 0 (Antineoplastic Agents) 0 (MAS1 protein, human) 0 (Proto-Oncogene Mas) |
| تواريخ الأحداث: | Date Created: 20240511 Date Completed: 20240525 Latest Revision: 20240531 |
| رمز التحديث: | 20240531 |
| DOI: | 10.1016/j.ejmech.2024.116477 |
| PMID: | 38733884 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1768-3254 |
|---|---|
| DOI: | 10.1016/j.ejmech.2024.116477 |